Colchicine did not significantly reduce the incidence of two common cardiovascular complications: Perioperative AF and myocardial injury after non-cardiac surgery (MINS). However, there was an encouraging signal of benefit for colchicine to reduce the incidence of adverse cardiovascular outcomes in patients undergoing major noncardiac thoracic surgery, which requires further study.

In this interview, David Conen, MD, MPH, and Joseph E. Marine MD, MBA, FACC discuss ESC Hot Line: COP-AF - Colchicine for the prevention of perioperative atrial fibrillation after major thoracic surgery.

Related References:

1. Conen D, Ke Wang M, Popova E, Chan MTV, Landoni G, Cata JP, Reimer C, McLean SR, Srinathan SK, Reyes JCT, Grande AM, Tallada AG, Sessler DI, Fleischmann E, Kabon B, Voltolini L, Cruz P, Maziak DE, Gutiérrez-Soriano L, McIntyre WF, Tandon V, Martínez-Téllez E, Guerra-Londono JJ, DuMerton D, Wong RHL, McGuire AL, Kidane B, Roux DP, Shargall Y, Wells JR, Ofori SN, Vincent J, Xu L, Li Z, Eikelboom JW, Jolly SS, Healey JS, Devereaux PJ; COP-AF Investigators. Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial. Lancet. 2023 Aug 25:S0140-6736(23)01689-6. doi: 10.1016/S0140-6736(23)01689-6. Epub ahead of print. PMID: 37640035.